Page 46 - Compass Pathways News Today

The business betting on magic mushrooms to treat depression 16 Dec, 2020 12:16 AM 6 minutes to read The healing properties of psilocybin mushrooms are being explored. Photo / Getty Images Other Back in the 1960s, George Goldsmiths use of magic mushrooms was purely recreational. "It was... an exploration like many people do when theyre younger. I found it really very interesting." Now magic mushrooms have propelled Goldsmith higher than he could ever have possibly imagined - to the helm of a com...

Noetic Psychedelic Fund LP Closing to New Accredited Investors December 31st, 2020 and Announcing the Launch of Noetic Fund II in February 2021 Noetic Funds," founded by the team at Grey House Partners GP Inc., is a pre-eminent venture fund led by experienced venture capitalists, hedge fund managers and operators to help nurture and grow companies poised to disrupt the traditional global pharmaceutical supply chain. Psychedelic medicine has the potential to cure global ailments, including the...

MONEYWEB app instead? Although psychedelics aren’t predicted to have the widespread recreational appeal of marijuana. By Tiffany Kary, Bloomberg 16 Dec 2020  00:54  Image: Roger Cremers/Bloomberg Cannabis is only on the cusp of many investors’ comfort zones, but the family offices and high-net-worth individuals hungry for early stage, edgy investments have already moved on to psychedelics. Marijuana’s legal headway in recent years has paved the way for new interest in remed...

Meet the Briton betting on magic mushrooms to help treat depression George Goldsmith, founder of Compass Pathways, has created a synthetic version of psilocybin, the active ingredient in magic mushrooms George Goldsmith, founder of Compass Pathways Credit: Compass Pathways Back in the 1960s, George Goldsmith’s use of magic mushrooms was purely recreational. “It was... an exploration like many people do when theyre younger. I found it really very interesting.” Now magic mushrooms have prop...

Dec 15, 2020 Cannabis is only on the cusp of many investors’ comfort zones, but the family offices and high-net-worth individuals hungry for early stage, edgy investments have already moved on to psychedelics. Marijuana’s legal headway in recent years has paved the way for new interest in remedies typically relegated to the black market. Companies that work with drugs like psilocybin, an ingredient in magic mushrooms, or Ibogaine, used in ayahuasca-style ceremonies, are proliferati...